Azelastine-fluticasone intranasal therapy: A paradigm shift in pediatric allergic rhinitis management. A point of view of the Italian Society of Pediatric Allergy and Immunology - PubMed
5 hours ago
- #allergic rhinitis
- #combination therapy
- #pediatric allergy
- Azelastine-fluticasone intranasal therapy is a significant advancement in pediatric allergic rhinitis (AR) management.
- The combination therapy offers superior efficacy compared to monotherapy, with rapid onset (15-30 min) and sustained symptom control.
- It addresses both early-phase (via H1-receptor antagonism) and late-phase (via glucocorticoid anti-inflammatory effects) allergic responses.
- Clinical trials in adolescents (12-18 years) confirm an excellent safety profile, with no significant effects on growth or HPA axis.
- Emerging evidence suggests potential utility in younger children (6-12 years).
- The SIAIP Delphi Consensus, involving 42 pediatricians, emphasized controlling type 2 inflammation, with over 80% agreement on key principles.
- Survey data from 864 Italian pediatricians managing 81,231 children shows high adherence to ARIA guidelines (>70%) and increased adoption of combination therapy (up to 20% of cases).
- The therapy aligns with contemporary guidelines and is increasingly used for moderate to severe AR in children and adolescents.